Concourse Financial Group Securities, Inc. Taysha Gene Therapies, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

21 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$1.13 - $2.9 $0 - $0
Q1 2025 May 14, 2025	BUY	$1.39 - $2.05 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$1.27 - $3.24 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$2.01 - $2.46 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$2.04 - $4.17 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$1.43 - $3.25 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.33 - $2.88 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.63 - $3.66 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.63 - $3.66 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.59 - $0.87 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.65 - $2.3 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.39 - $2.98 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.76 - $4.94 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$2.47 - $6.77 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.22 - $11.86 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$11.43 - $19.2 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$15.82 - $21.57 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$19.29 - $26.38 $0 - $0
Q1 2021 May 13, 2021	BUY	$20.3 - $31.75 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$19.14 - $28.13 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$22.4 - $24.47 $0 - $0

Others Institutions Holding TSHA

# of Institutions

153

Shares Held

245M

Call Options Held

107K

Put Options Held

17K

Rtw Investments, LP New York, NY

25M
Shares

$93.1 Million
0.89% of portfolio
Ra Capital Management, L.P. Boston, MA

23.6M
Shares

$87.6 Million
1.19% of portfolio
Avoro Capital Advisors LLC New York, NY

21.7M
Shares

$80.7 Million
0.91% of portfolio
Morgan Stanley New York, NY

16.9M
Shares

$62.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

12.8M
Shares

$47.8 Million
0.0% of portfolio

View Full List

About Taysha Gene Therapies, Inc.

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $180M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

More about TSHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account